Dermata Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative) - Licensing Agreements Member	12 Months Ended
	Dec. 31, 2023
March 31, 2017 \| First Amendment Member
Future milestone payments description	the Company was required to make future milestone payments to Villani in an aggregate amount of up to $20.25 million upon the achievement of specified development and sales milestones, payable in cash or in equity
July 30, 2021 \| Second Amendment Member
Future milestone payments description	the Company is required to make future milestone payments to Villani in an aggregate amount of up to $40.5 million upon the achievement of specified development and sales milestones, payable in cash or in equity